Role of liver biopsy in the era of direct-acting antivirals

Current Gastroenterology Reports

Volumn 15, Issue 2, 2013, Pages

  Gonzalez, Humberto C ^a   Jafri, Syed Mohammed ^a   Gordon, Stuart C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Acoustic Radiation Force Impulse; ASTto Platelet Ratio Index; Cirrhosis; Co infection hepatitis C and HIV; FIB 4; FibroIndex; Fibrometer; Fibrosure Fibrotest; Forns index; Hepascore; Hepatitis C; Liver Biopsy; Liver fibrosis; Liver transplant; Magnetic Resonance Elastography; Methacetin breath test; Transient Elastography

Indexed keywords

ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G;

ACOUSTIC RADIATION FORCE IMPULSE; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CARBON METHACETIN BREATH TEST; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC IMAGING EQUIPMENT; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ELASTOGRAPHY; FIB 4 SCORE; FIBROINDEX; FIBROMETER; FIBROSURE; FIBROTEST; FORNS INDEX; HEPASCORE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; MIXED INFECTION; NON INVASIVE PROCEDURE; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TRANSIENT ELASTOGRAPHY;

EID: 84872073834     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0307-z     Document Type: Article

References (74)

1. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-44.
2. Menghini G. One-second needle biopsy of the liver. Gastroenterology. 1958;35:190-9.
3. Bravo AA, Sheth SG, Chopra S. Liver Biopsy. N Engl J Med. 2001;344:495-500. (Pubitemid 32164902)
4. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002-June 10-12. Hepatology. 2002;36(5 Suppl 1):S3-S20.
5. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673-80.
6. Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat. 2006;13:762-9. (Pubitemid 44583502)
7. Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol. 2006;4:645-52.
8. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg. 2001;234:384-93.
9. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226-31. (Pubitemid 38155751)
10. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830-6. (Pubitemid 39434314)
11. Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl. 2007;13:975-83. (Pubitemid 47163189)
12. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc. 2001;33:1355-7.
13. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74.
14. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation. 2004;78:1308-11. (Pubitemid 39507969)
15. Baranova A, Lal P, Birerdinc A, et al. Non-invasive markers for liver fibrosis. BMC Gastroenterol. 2011;11:91.
16. Carey E, Carey WD. Noninvasive tests for liver disease, fibrosis, and cirrhosis: Is liver biopsy obsolete? Cleve Clin JMed. 2010;77:519-27.
17. Rockey D, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017-44.
18. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-8.
19. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15-20.
20. Eisenberg E, Konopniki M, Veitsman E, et al. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analag. 2003;96:1392-6. (Pubitemid 36512882)
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5. (Pubitemid 12218164)
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-9.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93. (Pubitemid 26260021)
24. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26. (Pubitemid 36919874)
25. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis Crelated fibrosis: an updatedmeta-analysis. Hepatology. 2011;53:726-36.
26. El-sayed R, Fahmy M, El Koofy N, et al. Can aspartate aminotransferase to platelet ratio index replace liver biopsy in chronic hepatitis C? Trop. Gastroenterology. 2011;32:267-72.
27. Toniutto T, Fabris C, Bitetto D, et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. Hepatology. 2007;22:1904-8. (Pubitemid 47525062)
28. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-21. (Pubitemid 47436137)
29. Singal AG, Thomassen LV, Gretch DR, et al. Use of the AST to platelet ratio index in HCV/HIV co-infected patients. Aliment Pharmacol Ther. 2011;33:566-77.
30. Cholongitas E, Tsochatzis E, Goulis J, et al. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transpl Int. 2010;23:861-70.
31. Beckebaum S, Iacob S, Klein CG, et al. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. Transplantation. 2010; 89:983-93.
32. Kamphues C, Lotz K, Rocken C, et al. Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients. Clin Transplant. 2010;24:652-9.
33. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25. (Pubitemid 43980111)
34. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCVinfection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-6. (Pubitemid 47171918)
35. Shah A, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci. 2011;56:3038-44.
36. Lu M, Lamerato L, Rupp LB, et al. Optimal noninvasive markers for fibrosis stage in chronic hepatitis C. Hepatology 2012;56(Suppl S1).
37. Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-73. (Pubitemid 41368177)
38. Becker L, Salameh W, Sferruzz A, et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7:696-701.
39. Kalantari H, Hoseini H, Babak A, et al. Validation of hepascore as a predictor of liver fibrosis in patients with chronic hepatitis C infection. Hepat Res Treat. 2011;2011:972759.
40. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775-82. (Pubitemid 46529041)
41. Cacoub P, Carrat F, Bedossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study - ANRS HC02. J Hepatol. 2008;48:765-73.
42. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-92.
43. Duarte-Rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily practice. Ann Hepatol. 2012;11:426-39.
44. Braden B, Faust D, Sarrazin U, et al. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2005;21:179-85. (Pubitemid 40222971)
45. Lalazar G, Pappo O, Hershcovici T, et al. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat. 2008;15:716-28.
46. Koda M, Matunaga Y, Kawakami M, et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007;45:297-306. (Pubitemid 46374586)
47. Halfon P, Penaranda G, Renou C, et al. External validation of FibroIndex. Hepatology. 2007;46:280-1.
48. Adler M, Gulbis B, Moreno C, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology. 2008;47:762-3. (Pubitemid 351280750)
49. Cales P, Boursier J, Oberti F, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32(6 Suppl 1):40-51.
50. Cales P, Halfon P, Batisse D, et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/ HCV co-infection. J Hepatol. 2010;53:238-44.
51. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIVand hepatitis C virus co-infected patients. AIDS. 2003;17:721-5. (Pubitemid 36521078)
52. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49:450-4. (Pubitemid 36250205)
53. Imber-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-75. (Pubitemid 32322537)
54. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FIbroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. 2004. Comp Hepatol. 2004;3:8.
55. Shaheen AA,Wan AF, Myers RP, et al. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102:2589-600. (Pubitemid 47631778)
56. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a metaanalysis. Gastroenterology. 2008;134:960-74.
57. Fraquelli M, Rigamonti C, Casazza G, et al. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol. 2010;54:621-8.
58. Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718-23.
59. Tapper EB, Cohen EB, Patel K, et al. Levels of alanine aminotransferease confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2012;10:932-7.
60. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;53:828-35.
61. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTATIC study). J Hepatol. 2010;53:1013-21.
62. Adebajo CO, Talwalkar JA, Poterucha JJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012;18:323-31.
63. Kirk GD, et al. Assessment of liver fibrosis by transcient elastogrpahy in persons with hepatitis c virus infection or HIV-hepatitis c virus coinfection. Clin Infect Disease. 2009;48(7):963.
64. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007;5:1207-13.
65. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135:32-40. (Pubitemid 351899024)
66. Lee VS, Miller FH, Omary RA, et al. Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients. Transplantation. 2011;92:581-6.
67. Rafai K, Cornberg J, Mederacke I, et al. Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis. 2011;43:491-7.
68. Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int. 2009;30:538-45.
69. Son YC, Kim SU, Han WK, et al. Normal liver elasticity values using acoustic radiation force impulse imaging: a prospective study in healthy living liver and kidney donors. J Gastroenterol Hepatol. 2012;27:130-6.
70. Chen SH, Li YF, Lai HC, et al. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. BMC Gastroenterol. 2012;12:105.
71. Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenteol. 2011;106:2112-20.
72. Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int. 2011;31 Suppl 1:13-7.
73. Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC, et al. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol. 2007;31:504-9. (Pubitemid 46877550)
74. Lai M, Afdhal NH. Editorial: staging liver fibrosis in hepatitis C: a challenge for this decade. Am J Gastroenterol. 2011;106:2121-2.